Professionals 210 results
Capabilities 65 results
Practice Area
Practice Area
Class Actions & Group Litigation
Industry
Experience 13 results
Experience
|June 28, 2024
Agreement Between 119 Institutional Investors and the Company Vivendi SE
Insights & News 368 results
Recognitions
|November 6, 2024
|1 Min Read
Winston & Strawn Named a Leading Firm Taking Care of the Planet in Lamp House’s Annual Report
Government Program Fraud, False Claims Act & Qui Tam Litigation Playbook
|October 30, 2024
|5 Min Read
Despite an earlier declination of intervention in United States ex rel. Zafirov v. Florida Medical Associates, LLC, Case No. 8:19-cv-01236-KKM-SPF (M.D. Fla. Sept. 30, 2024), yesterday, the United States filed a notice of appeal of the Zafirov Court’s September 30, 2024 decision to dismiss the case to the U.S. Court of Appeals for the Eleventh Circuit. The district court held in the underlying dismissal order that the qui tam provisions of the False Claims Act (FCA) are unconstitutional, echoing arguments made by certain justices in a recent FCA case before the U.S. Supreme Court. The relator, Dr. Clarissa Zafirov, filed suit in 2019 against her employer, Florida Medical Associates, LLC, alleging that the physician practice group violated the FCA by misrepresenting patient medical conditions to Medicare. Like most relators, Zafirov did not assert that any of the alleged illegality harmed her personally; rather, she brought suit on behalf of the “real party of interest,” the United States of America. The government had declined to intervene, leaving Zafirov to pursue the litigation on her own over the past five years. But yesterday, the United States filed its Notice of Appeal, opening the door for further review of the constitutionality of the FCA's qui tam provisions – including by the U.S. Supreme Court should there be a circuit split.
Product Liability & Mass Torts Digest
|October 28, 2024
|4 Min Read
Third-party litigation financing is a significant issue in the U.S. legal system, with its use playing an increasingly important role in litigation. Whether a party should be, or is, required to disclose litigation funding from a third party, and the terms of that funding, has been the subject of heated debate for some time.
Other Results 20 results
Location
Location
Law Glossary
Where Is a List of Biosimilar Drugs and Biologics That Have Been Approved in the U.S.?